#Human japanese version 2.0 vs version 3.0 skin
Itch NRS and Skin Pain NRS scores may range from 0 (no itch/pain) to 10 (worst imaginable itch/pain). None of the patients reported clinically diagnosed anxiety disorder or depression.ĭata are presented as median (Q1–Q3), tested using the Wilcoxon rank sum test. Notably, 10 (14%) patients had both anxiety symptoms and depressive symptoms. Seventy-three patients were included in the analysis (male, 82% median age, 54 years), 3 and anxiety symptoms and depressive symptoms occurred in 20 (27%) and 16 (22%) patients, respectively (Table 1). 8 Anxiety symptoms and depressive symptoms were defined as a baseline GAD-7 score of ≥5 4 and baseline PHQ-8 score of ≥5, 5, 9 respectively.
#Human japanese version 2.0 vs version 3.0 pro
The outcomes of interest were the Psoriasis Area and Severity Index (PASI) score and PRO scores captured using an electronic system at baseline, such as the Generalized Anxiety Disorder-7 (GAD-7), 4 Patient Health Questionnaire-8 (PHQ-8), 5 Dermatology Life Quality Index (DLQI), European Quality of Life 5-Dimension 5-Level Utility Index (EQ-5D-5L UI) calculated using the Japanese tariff, 6 Activity Impairment domain of the Work Productivity and Activity Impairment-Psoriasis questionnaire (WPAI-PSO AI) 7 and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). 3 Patients (aged ≥18 years) who had plaque psoriasis without peripheral arthritis symptoms and were eligible for self-administration of brodalumab were enrolled at 15 facilities across Japan (study period, October 2017–March 2020). We assessed the association of anxiety symptoms and depressive symptoms with the severity of psoriasis, psoriatic symptoms, health-related quality of life (HRQoL) and satisfaction levels in Japanese patients with psoriasis using baseline data of participants from a single-arm, open-label, multicentre, prospective cohort study – ProLOGUE (Japan Registry of Clinical Trials identifier: jRCTs031180037). 1, 2 To date, however, evidence for the association of these symptoms with patients’ direct perception of their disease (called patient-reported outcomes ) remains limited.
Anxiety symptoms and depressive symptoms are observed in approximately 20%–50% and 30% of patients with psoriasis, respectively.
0 kommentar(er)
